CRISPR Therapeutics AG Nam.-Akt (1CG.SG)
| Previous Close | 40.80 |
| Open | 38.20 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 37.80 - 38.40 |
| 52 Week Range | 37.80 - 40.80 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress
ZUG, Switzerland and CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that an abstract providing safety and efficacy data from the ongoing CTX130™ clinical trial for patients with T-cell lymphoma has been accepted for oral presentation at the Annual European Hematology Association (EHA) 2022 Hybrid Congress, taking place June 9 – 12, 2022
- GlobeNewswire
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
- More than 75 patients dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; planned global regulatory submissions on track for late 2022- -Initiated two new CTX001 Phase 3 clinical trials in pediatric patients with TDT and SCD- -Enrollment and dosing ongoing for CTX110™, targeting CD19+ B-cell malignancies; additional data expected to report in 2022- -Updates from ongoing CTX120™ and CTX130™ clinical trials anticipated in 1H2022- ZUG, Switzerland and CAMBRIDGE, Mass., May 09, 202
- Simply Wall St.
How Many CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Do Institutions Own?
If you want to know who really controls CRISPR Therapeutics AG ( NASDAQ:CRSP ), then you'll have to look at the makeup...
